Hvivo Share Price (HVO)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Hvivo	LSE:HVO	London	Ordinary Share	GB00B6ZM0X53	ORD 5P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	29.00p	35,000	08:00:12

Bid Price		Offer Price	High Price	Low Price	Open Price
28.00p		30.00p	29.00p	29.00p	29.00p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	10.88	-14.82	-16.50		23.4

Related Shares
Smith & Nephew (SN.), NMC Health (NMC), Netscientific (NSCI), Widecells (WDC)

Hvivo (HVO) Latest News

Hvivo News

Date	Time	Source	Headline
10/1/2019	09:59	ALNC	hVIVO Meets Primary Endpoint In Phase II Vaccine Flu Study
10/1/2019	07:42	ALNCF	Alliance News Flash Headline
10/1/2019	07:00	UKREG	hVIVO plc Positive data for Phase IIb FLU-v challenge study
04/1/2019	16:00	UKREG	hVIVO plc Director's Dealings
04/1/2019	10:02	UKREG	hVIVO plc Award of Share Options
02/1/2019	07:00	UKREG	hVIVO plc Directorate Change
20/11/2018	07:00	UKREG	hVIVO plc Exercise of Share Options
31/10/2018	10:30	ALNC	hVIVO Gets Encouraging Results From Mosquito Disease Vaccine Proposal
31/10/2018	07:00	RNSNON	hVIVO plc Partial preliminary results for NIH study of AGS-v
08/10/2018	13:00	UKREG	hVIVO plc Director's Dealings

More Hvivo News

Hvivo Takeover Rumours

Hvivo (HVO) Share Charts

1 Year Hvivo Chart

1 Month Hvivo Chart

Intraday Hvivo Chart

Hvivo (HVO) Discussions and Chat

Hvivo Forums and Chat

Date	Time	Title	Posts
21/1/2019	11:43	hVIVO plc	2,573

Add a New Thread

Hvivo (HVO) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-01-21 16:19:08	28.10	15,000	4,215.00	O
2019-01-21 16:18:55	28.34	20,000	5,668.02	O

View all Hvivo trades in real-time

Hvivo (HVO) Top Chat Posts

Date	Subject
21/1/2019 08:20	Hvivo Daily Update: Hvivo is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 29p. Hvivo has a 4 week average price of 25.50p and a 12 week average price of 18.50p. The 1 year high share price is 109p while the 1 year low share price is currently 15.50p. There are currently 80,593,592 shares in issue and the average daily traded volume is 129,064 shares. The market capitalisation of Hvivo is £23,372,141.68. Read Full Thread Reply
17/1/2019 18:22	mam fach: Sneaky. Don't want share price to rise obviously. Hang on to your shares, Read Full Thread Follow Reply
10/1/2019 12:41	researchanalyst1: Economic theory suggests human beings are rational agents and their investment ideas are goal-oriented, evaluative, consistent and free from emotions. However, in reality, the investment behaviour of retail investors can often be irrational. Here’s why: According to Redmayne Bentley’s latest market factsheet, retail investors, aka PIs, typically sell stocks that, on average, outperform the main market. One important reason for this is the ‘disposition’ effect. It is the tendency to sell stocks of which prices have risen since the time of purchase. Such stocks may have the potential to re-rate exponentially due to a material event. This, nevertheless, is invisible to the retail investor who is simply focussed on booking a quick profit; the proceeds of which are then used to ‘average down’ an underperforming stock. Thus, retail investors tend to sell the winners and hold on to the losers. A case in point is London-listed hVIVO Plc, a junior biotech pioneering human disease models based upon viral and allergen challenge. It’s abundantly clear that sections of retail investors, hell-bent on banking miniscule profits, continue to miss the glaringly obvious point about hVIVO Plc; the company is materially mispriced. Period. And as expected, the four Market Makers on the stock are currently throwing a staggering level of ‘head fakes’ to secure cheap stock – such a text book tactic yet it always lures the naïve investor into selling too early. So, what’s the deal with hVIVO Plc? • At the current share price of 37p, HVO is trading marginally above its cash position; at the end of September 2018, and following receipt of an R&D tax credit of £2.5 million, the company had net cash and cash equivalents of £13.4m. • For the six months ended 30 June 2018, revenue was £4.9 million, an increase of 23.6% against H1 2017. • For the six months ended 30 June 2018, gross profit was £1.2 million. • A new client contract was signed for £11.9 million in September 2018 and commenced thereafter in October 2018. This will be realised as revenue in H2 2018 and during 2019. • As indicated in the company’s interim results, substantive contract negotiations, with top-tier pharmaceutical companies no less, are currently taking place. These should lead to contract signatures in 2019. • As indicated in the company’s interim results, and as announced by the company’s Executive Chairman, Dr Trevor Phillips, HVO is experiencing a significant level of interest from leading pharmaceutical companies for the development of new challenge models in RSV, asthma and COPD. As a result, the company expects to convert a number of these into contracts. • Finally, and probably the most valuable aspect of HVO, the company’s universal flu vaccine candidate, FLU-v, continues to materially outperform market expectations thereby placing it firmly on the radar of big pharma. Remember, FLU-v is currently knocking at the door of what is now a multibillion dollar market. So, let’s do the sums. The company’s current market cap is £27.6m (37p). Less cash and cash equivalents of £13.4m means the market is collectively valuing the hVIVO platform at a paltry £14.2m! Yes, feel free to bark the unsavoury but apt remark, “What the ….!” This – premium quality assets at fire-sale prices– is not only unwarranted, but implies an extraordinary disconnection with the fundamentals. Subsequently, Numis have this morning issued a BUY note with a multibagging target price. Https://www.numiscorp.com/x/login.html?req=/research/2019-01/hVIVO_Company%2520Note_10Jan19.pdf Read Full Thread Follow Reply
13/11/2018 10:40	bernymadoff: The majority of people form opinions not based on company assets, financials and fundamentals but purely on the direction of the share price. They actually believe the Share Price is accurate/correct and true on a day-to-day basis regardless of the external factors that may affect it such as shorting, forced sellers etc. The biggest gains I have had on AIM by far have been my conviction buys that I've held for many months and sometimes well over a year. I have no doubt this will be right up there with the best of them. Read Full Thread Follow Reply
26/9/2018 07:51	tonyw99: I'm not saying either way but it doesn't matter when the options are exercised. They can be exercised (and then held) at any point for 8p and sold whenever she wants / needs cash. They wouldn't have "been allowed / advised" to cash them in at 160p - 210p because of the message it would give to the market - we're cashing out because we don't see any more upside. They could well be lining up a big payday however.....I'm not sure why the share price would spike on the back of it. If they sell as expected then they'll need the cash to run the service business. So unless they are going to return it to shareholders, that could be the only big gain. At which point, max capacity on revenue is c. £40m and a 10% return on ebitda would give off £4m. It wouldn't warrant a share price of more then £1 on 20 times PE Read Full Thread Follow Reply
19/9/2018 09:49	discojames: a1samu if youre going to deramp at least put ome effort in to it. "The share price will continue to collapse on lack of news", thats a blatant false premise as the share price hasnt collapsed and in fact has barely moved in over 2 months. Read Full Thread Follow Reply
19/9/2018 07:44	a1samu: The Directors have nothing concrete to report in the form of hard facts. There will be a lot of hot air of the future and potential and likely deals with unnamed parties, which will evaporate and the share price will continue to collapse on lack of news. They already released an RNS to say that news is imminent and we are still waiting. If there would be substantial news, like 10x bag value increase, they would not be able to hold it for the interim publication. Any substantial news they would be duty bound by the stock exchange rules to release immediately. As is, expect mediocre rubbish news tomorrow and further share price weakness, after perhaps a bounce, if lucky! Read Full Thread Follow Reply
30/8/2018 07:53	discojames: I disagree, Berny. Any test, with any sample size has the possibility to be flawed. Getting parallel results from an independent body is actually important to verify them and the next step up in the share price. Every party involved (us included) will be very happy to hear that a third party has backed up the incredible results so far, and I can see it having a large affect on the share price. Any major in talks with HVO over Flu-V will be waiting on this verification, why would they sign a deal now when they are so close to reading the NIH findings, unless such a deal included a get-out clauses if NIH results don't back up those of HVO's. It will then just be a question of when rather than if a deal will be signed to move Flu-V to the next stage. I would prefer a takeover or a sale of the rights over a joint venture (I think HVO are targetting the latter), but any of these options work for us obviously, in terms of the share price Read Full Thread Follow Reply
13/7/2018 22:48	applegarthlse: Not the first time shorters have gone after Neil Woodford? Read this article......Woodford slates Kerrisdale for shorting ProthenaFeature29 JAN 2018Neil Woodford hasn't held back in his criticism of the US hedge fund, Kerrisdale Capital, which recently moved to short one of his fund's top holdings, Prothena (PRTA.O).COMMENTWoodford Ingrid SmithIrish biotech company Prothena forms a relatively significant chunk of the Woodford Patient Capital Trust (WPCT).In November 2017 Kerrisdale published a less than positive 29-page report on Prothena, explaining why it had chosen to short the company's shares to inevitably profit from a fall in the share price, which saw a fall of nearly 28 per cent in Dollar terms on the Nasdaq.SPONSORED CONTENT Kubernetes on Windows are we crazy?Kubernetes on Windows are we crazy?By G-ResearchThe drop in Prothena's share price has cost it its top spot in the Patient Capital portfolio. From being the biggest holding at over 16 per cent of assets in October, it dropped to number two at 9.2 per cent by December, behind Oxford Nanopore, an unlisted university seeking to revolutionise DNA analysis.In its report, Kerrisdale argued that trials on Prothena's main drug under development an antibody used to treat a rare disease called amyloidosis is likely to fail and predicted Prothena will be 'the next big biotech blowup'.Woodford for his part said he is confident that Prothena, whose shares have rallied 20 per cent since the beginning of the New Year, will publish successful trial results in the second quarter, and forecasts there will be good news from other investments.'The next 6-12 months should see some important inflexion points, Woodford said. He added, "We are very confident about the portfolio", and said many companies in the Woodford Patient Capital Trust are "on the cusp" of a breakthrough.Some market watchers see Kerrisdale's comments as just another example of the long running feud between the hedge fund's founder, Sahm Adrangi, and Woodford.It was less than three years ago that Kerrisdale forecast shares in Allied Minds a technology venture capitalist and another of the fund manager's long-term holdings would tumble, describing many of its investments as 'duds'.Woodford has said Kerrisdale's raison d'etre is to frighten the market at a time when the market welcomes being frightened."It doesn't matter if what they said about Allied Minds and Prothena is totally inaccurate and unsubstantiated," Woodford told investors recently at a Winterflood Securities event in London.The star fund manager also argues that the financial press has a lot to answer for, by giving Kerrisdale "the oxygen of publicity" in order to achieve the self-fulfilled prophecy of a share price fall.The last year for Neil Woodford could be viewed as his very own annus horribilis, with all three of his funds having experienced a downturn in performance as key holdings have struggled including the Woodford Equity Income fund which also invests in Prothena.And Woodford Patient Capital, which is an investment trust focused on early stage healthcare and technology companies, has certainly fared the worst.Since its inception in 2015 the fund's shares have fallen over 17 per cent to 83.4p, having lost 7 per cent of their value in 2017 and 9.75 per cent in 2016. This contrasts to August 2015, when they they were reported to show a 15 per cent premium over net asset value (NAV), but now trade at an 8.7 per cent discount to NAV.However, falls in the value of the underlying portfolio of 81 companies have been smaller, and the trust has still been able to report successes amongst it portfolio holdings mostly notably from online estate agent Purplebricks(PURP), whose shares significantly jumped 194 per cent in 2017, according to Woodford Investment Management. Read Full Thread Follow Reply
10/7/2018 18:41	snakesbelly: Found this article about Woodford and must admit makes me worried about his judgements ? Just hope he's called this one right ? .......................Few UK investors would have heard of Kerrisdale Capital three years ago, but after two high-profile victories against Neil Woodford, the small New York-based hedge fund is getting a name for itself on these shores.The collapse in the shares of Prothena (PRTA.O) this week after the failure of its flagship drug has richly rewarded Kerrisdale, which was 'shorting', or betting against, the stock, and punished Woodford, the biotech company's biggest investor. Kerrisdale labelled Prothena 'the next big biotech blow-up' in November as it announced its short on the stock, claiming the shares could fall as much as 80% and saying it was 'certain' of the failure of NEOD001, a potential therapy for AL Amyloidosis, a rare disease caused by the build-up of amyloid proteins.Less than six months later, Kerrisdale has been vindicated. Prothena has ceased further research into the drug after the failure of the phase 2b Pronto study into the treatment. The shares are down 82% since Kerrisdale started shorting them.It's the second time Kerrisdale, a small hedge fund operation running around $150 million (£108 million) in assets, has taken on Woodford, who ran £17.8 billion at the last count.In 2015, Kerrisdale launched a short-selling attack on long-term Woodford holding Allied Minds (ALML), branding the company, which commercialises intellectual property from universities, 'a dressed up collection of high-risk, low-reward gambles' and saying the shares could fall by 'at least' 70%. Three years on, the shares are down 78%.Both episodes have delivered major blows to Woodford's funds. Allied Minds was a top 10 holding when Woodford launched his Woodford Patient Capital (WPCT) investment trust in 2015, and sat just outside the top 10 when he launched his Woodford Equity Income fund a year earlier.Over the three years to the end of March, no stock has weighed more heavily on the performance of his Woodford Equity Income fund than Allied Minds, in a period that has also feature heavy share price falls from holdings like Provident Financial (PFG), Capita (CPI) and AA (AAAA). Prothena's impact on the Woodford Patient Capital investment trust has been even more dramatic. Prothena was the trust's largest holding when Kerrisdale launched its attack, representing a huge 16.3% of the fund's assets, although that had fallen to 9.1% by the end of March. The stock's 69% collapse on Monday saw shares in Woodford's trust tumble by more than 10%.The Woodford Equity Income fund, which held a 3.1% stake at the end of last month, and the Income Focus fund, with a 1.8% holding, have also been dented.Prothena's fall is likely to sting all the more for Woodford given Kerrisdale was a beneficiary, following the war of words between the two.Woodford branded Kerrisdale's Allied Minds attack as 'opportunistic', going further after the hedge fund took aim at Prothena.'Their job is to scare the market when the market is prepared to be scared. It doesn't matter if what they said about Allied Minds and Prothena is totally inaccurate and unsubstantiated,' he said earlier this year.'What matters is Bloomberg and others giving them the oxygen of publicity and hey presto there is a self-fulfilled prophecy and the share price falls.'Kerrisdale had in turn gone on the attack against the UK's most famous fund manager, arguing in its 29-page report on Prothena that investors should be wary of Woodford's 'repeated large mistakes in the biotech sector'.On Twitter, Kerrisdale claimed Woodford would 'lose money on your bad investments regardless of whether we write on them. But hopefully our work helps the widows and orphans who invest in your Patient Capital trust recognise how poor your diligence is on the stocks you pick'. Read Full Thread Follow Reply
06/7/2018 06:33	bernymadoff: IP are selling a few into a rising share price. That sale was made on Tuesday. We know that at the same time they've been selling Woodford has been buying. Actually Woodford is buying much more aggressively than they have been selling. Hence the share price has continued to rise. The rising share price tells us all we need to know which way the balance is tilted here Read Full Thread Follow Reply

Hvivo share price data is direct from the London Stock Exchange

Your Recent History

LSE

HVO

Hvivo

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190122 02:18:45